Literature DB >> 3098920

The metabolism of [18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat.

P Cumming, B E Boyes, W R Martin, M Adam, J Grierson, T Ruth, E G McGeer.   

Abstract

The metabolism of the positron-emitting compound [18F]6-fluoro-L-3,4-dihydroxyphenylalanine (*F-DOPA) was studied in carbidopa-pretreated male hooded rats. Thirty minutes following carbidopa administration (5 mg/kg i.p.), animals received *F-DOPA (500 micrograms/kg; specific activity, 175-230 Ci/mol) as an intrajugular bolus. Blood samples were taken at various times between 5 and 90 min, and the plasma was analyzed by HPLC with gamma counting of fractions. *F-DOPA disappeared rapidly from plasma in concert with the formation of the 3-O-methylated metabolite, Me-*F-DOPA. Animals were killed from 5 to 120 min after injection, and the brains were rapidly dissected. The disappearance of *F-DOPA from both vermis and striatal samples was rapid. Me-*F-DOPA, the sole metabolite observed in the vermis, was the major labeled material in the striatum at greater than or equal to 20 min after injection. Fluorodopamine was an important metabolite in the striatum, making up 25% of total radioactivity at early intervals. Striatal samples also contained fluoro-3,4-dihydroxyphenylacetic acid, which constituted approximately 10% of the total radioactivity, and traces of two radiolabeled compounds, tentatively identified as fluorohomovanillic acid and fluoro-3-methoxytyramine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3098920     DOI: 10.1111/j.1471-4159.1987.tb04135.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

Review 1.  Approaches to the design of biochemical probes for positron emission tomography.

Authors:  J R Barrio
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

Review 2.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

4.  Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.

Authors:  V Kaasinen; R P Maguire; H-P Hundemer; K L Leenders
Journal:  J Neurol       Date:  2005-10-18       Impact factor: 4.849

5.  Evaluation of mono- and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system.

Authors:  S M Tejani-Butt; M Hauptmann; A D'Mello; A Frazer; J M Marcoccia; D J Brunswick
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

6.  Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET.

Authors:  Keisuke Matsubara; Yoko Ikoma; Maki Okada; Masanobu Ibaraki; Tetsuya Suhara; Toshibumi Kinoshita; Hiroshi Ito
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

7.  Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.

Authors:  P Hartvig; K J Lindner; J Tedroff; P Bjurling; K Hörnfelt; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.

Authors:  P Hartvig; H Agren; L Reibring; J Tedroff; P Bjurling; T Kihlberg; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991

9.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

10.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

Authors:  Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur
Journal:  Arch Gen Psychiatry       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.